Stepwise pathology resolved almost every ambiguous cutaneous melanocytic tumor
Ambiguous cutaneous melanocytic tumors remain one of dermatopathology’s most difficult problems. Under the microscope, these lesions can sit between benign nevus and melanoma, and the wrong label can push patients toward either undertreatment or unnecessary escalation. In this prospective cohort from a tertiary dermatopathology referral center in the Netherlands, a structured pathway using expert histopathologic review first, then molecular testing when needed, delivered a definitive diagnosis in 966 of 994 patients, or 97.2%.
The workflow mattered because the biological stakes were real. A lesion that looks deceptively bland can still harbor the molecular and clinical behavior of melanoma, while a lesion with worrisome architectural disorder may ultimately prove nonmalignant after expert review and genomic correlation. The study treated diagnosis as a clinicopathologic problem rather than a purely visual one, and the outcome data support that approach.
Among 258,562 patients with excised melanocytic tumors nationwide, 2,685 had lesions considered ambiguous by referring pathologists. That small fraction, 1.0%, still generated a large downstream diagnostic burden. From that pool, 994 patients entered the prospective cohort between September 2018 and December 2021.
Expert review alone settled 42% of cases before molecular escalation
A single expert histopathologic evaluation was enough to classify 417 tumors, or 42.0% of the cohort. The remaining 549 diagnoses, or 55.2%, required molecular analyses after the initial review remained inconclusive. Those assays included next-generation sequencing, single-nucleotide polymorphism array, and targeted RNA sequencing.
This is where the diagnostic model becomes especially practical. Histology remains the first language of melanocytic pathology, but ambiguity often reflects a lesion’s intermediate biology rather than a deficiency of the pathologist. Molecular profiling can separate copy-number instability, oncogenic signaling patterns, and transcriptomic signatures that are otherwise invisible on routine stains. In a field where morphology alone can be misleading, the added genomic layer helped transform uncertainty into a usable classification.
The final diagnoses split into three clinically meaningful groups: 608 patients, or 61.2%, received a nonmelanoma diagnosis; 358 patients, or 36.0%, were diagnosed with melanoma; and 28 patients, or 2.8%, were classified as borderline melanoma. The borderline category is small, but it captures the gray zone where biology and morphology do not fully agree and where management often depends on careful surveillance rather than binary thinking.
Long-term outcomes aligned with the final diagnostic categories
The most persuasive part of the study was not only diagnostic resolution, but whether those diagnoses held up over time. They did.
Among patients classified as nonmelanoma, no melanoma-related events occurred during a median follow-up of 5.4 years. The incidence was 0.0%, with a 95% confidence interval of 0.0 to 0.6. That is the kind of follow-up signal clinicians want when deciding whether a lesion truly behaves as benign disease. A misclassified melanoma would be expected to declare itself through recurrence, metastasis, or another melanoma-related event; none did in this group.
Patients diagnosed with melanoma followed a different course, as expected for a biologically malignant process. During a median follow-up of 5.0 years, 20 patients developed melanoma-related events. Among 186 patients who underwent sentinel node biopsy, 33, or 17.7%, had a positive result. Sentinel node positivity is not just a staging detail. It reflects the lesion’s ability to spread beyond the primary site and confirms that the diagnostic pathway was identifying tumors with genuine metastatic potential.
The borderline melanoma group was small, but it remained clinically informative. No events occurred among the 28 patients assigned to that category. Even so, the sample is too small to treat that result as a universal rule. Borderline lesions are precisely the cases where the treating team must reconcile histology, molecular profile, and the patient’s broader clinical context.
Why molecular classification changed the meaning of ambiguous histology
The study reinforces an important point about melanocytic pathology: ambiguity is not a final diagnosis. It is a signal that the tumor sits at the edge of existing morphologic categories, and that deeper interrogation may be needed before prognosis is assigned. Molecular analysis adds a second axis of evidence, especially when spindle-cell architecture, atypical junctional growth, unusual maturation, or mixed cytologic features prevent a confident call on morphology alone.
In practice, the benefit is twofold. Patients with true melanoma are less likely to be falsely reassured, and patients with nonmelanoma tumors are less likely to be exposed to overtreatment, repeated procedures, or needless anxiety from a malignant label. The study also shows that expert review is not redundant even in the molecular era. A substantial fraction of cases were solved by expert histopathology before genomic testing was needed, suggesting that subspecialty review remains the first and most efficient filter in ambiguous lesions.
The long-term event data strengthen the clinical validity of this sequence. Diagnostic categories that emerged from the stepwise model were not merely tidy labels in a pathology report; they tracked with actual melanoma outcomes over years of observation. In a domain where a false-positive diagnosis can be costly and a false-negative diagnosis can be dangerous, that alignment carries real weight.
What the cohort means for melanoma pathology practice
This cohort from a national referral pathway shows that a centralized expert-plus-molecular approach can resolve nearly all ambiguous primary cutaneous melanocytic tumors. The study also provides one of the clearest long-term validations yet for this style of classification, because the final diagnoses correlated with melanoma-related events in the expected direction.
The remaining challenge is not whether the approach works in expert hands. It is how broadly the model can be implemented, what it costs, and how consistently similar performance can be reproduced outside a specialized referral center. Ambiguous melanocytic tumors will continue to test the limits of morphology, and future practice will depend on whether community pathways can access the same level of dermatopathology expertise and molecular support without delay.